Idioma:

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision

Sousa, AC ; Silveira, C. ; Janeiro, A. ; Malveiro, S. ; Oliveira, AR ; Felizardo, M. ; Nogueira, F. ; Teixeira, E. ; Martins, J. ; Carmo-Fonseca, M.

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.35-40 [Periódico revisado por pares]

Ireland: Elsevier B.V

Texto completo disponível

Citações Citado por

Enviar para

Título:
Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision
Autor: Sousa, AC ; Silveira, C. ; Janeiro, A. ; Malveiro, S. ; Oliveira, AR ; Felizardo, M. ; Nogueira, F. ; Teixeira, E. ; Martins, J. ; Carmo-Fonseca, M.
Assuntos: Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - genetics ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Decision Making ; DNA Mutational Analysis - methods ; EGFR ; ErbB Receptors - genetics ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Molecular diagnosis ; Mutation ; NSCLC ; Prognosis ; Protein Kinase Inhibitors - therapeutic use ; Tyrosine-kinase domain mutations ; Young Adult
É parte de: Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.35-40
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: •Approximately 3% of NSCLC patients have uncommon genetic alterations in the EGFR gene.•We report six new single mutations previously unidentified in NSCLC patients.•We report seven novel combinations of doublet mutations. Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKIs). Thus, EGFR genotyping provides crucial information for treatment decision. Both Sanger sequencing and real-time PCR methodologies are used for EGFR genotyping. However, methods based on real-time PCR have limitations, as they may not detect rare or novel mutations. The aim of this study was to determine the prevalence of rare mutations in the tyrosine kinase domain (exons 18–21) of the EGFR gene not targeted by the most frequently used real-time PCR approaches, i.e., the cobas® EGFR Mutation Test, and the Idylla™ EGFR Mutation Assay. A total of 1228 NSCLC patients were screened for mutations in exons 18–21 of the EGFR gene using Sanger sequencing. We observed that 252 patients (∼20%) had at least one mutation in the EGFR gene, and 38 (∼3%) carried uncommon genetic alterations that would not be identified by the cobas® or the Idylla™ tests. We further found six new single mutations and seven previously unreported compound mutations. Clinical information and patient outcome are presented for these cases. This study highlights the value of sequencing-based approaches to identify rare mutations. Our results add to the inventory of known EGFR mutations, thus contributing to improved lung cancer precision treatment.
Editor: Ireland: Elsevier B.V
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision

Sousa, AC ; Silveira, C. ; Janeiro, A. ; Malveiro, S. ; Oliveira, AR ; Felizardo, M. ; Nogueira, F. ; Teixeira, E. ; Martins, J. ; Carmo-Fonseca, M.

Ireland: Elsevier B.V

Buscando em bases de dados remotas. Favor aguardar.